Clinical Trial Update: Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating topotecan hydrochloride or CRLX101 (cyclodextrin-based polymer-camptothecin) for recurrent small cell lung cancer; trial ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CRLX101
• Topotecan hydrochloride (topotecan hydrochloride)

Snippet

Sponsor: University of Chicago | Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-04-14